Results First Quarter 2007
Oslo, Norway, 25 April 2007
Photocure ASA (Oslo Stock Exchange: PHO) presents today its results for the first quarter of 2007. The main items of the report are:
- Sales revenues amounted to NOK 19.0 million (13.3), an increase of 43%.
- Significantly strengthened marketing and sales organisation.
- Net loss amounted to NOK -17.8 million (43.0).
- Liquid assets amounted to NOK 316.8 million at the end of the period.
- Metvix presented as first line treatment for actinic keratosis in international PDT guidelines.
- Successfully completed two phase III studies for Metvix/Aktilite in the US.
- Started phase II study for treatment of moderate to severe acne in the US.
- Presented first data from phase I/II study in detection of colon cancer.
- Filed two new patents for combination of PCI technology and siRNA/PNA.
President and CEO of Photocure, Dr. Kjetil Hestdal, says in a comment to the results: "We are pleased to see growing sales for Metvix and Hexvix, and will further strengthen our sales efforts in order to realise the full potential of our innovative products."
For further information, please contact:
President and CEO Kjetil Hestdal
E-mail: kh@photocure.no
Mobile: +47 913 19 535
CFO Christian Fekete
E-mail: cf@photocure.no
Mobile: +47 916 42 938
www.photocure.com
Photocure ASA is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of different types of cancer.
Photocure has three products on the market: Metvix® cream combined with the Aktilite® lamp for the treatment of sun-damaged skin and certain types of skin cancer, and Hexvix® for the diagnosis of bladder cancer. In addition, the company has several follow-on products and technologies in the pipeline.